Ridgeback Biotherapeutics

Pfizer Inc. PFE 2.79% expects demand for its Covid-19 antiviral drug to increase as governments return to replenish their supplies and…

The Covid-19 pill from Pfizer Inc. failed to prevent symptomatic infections in adults who had been exposed to the pandemic virus, a…

Researchers and U.S. health regulators worry Covid-19 will figure out a way to evade important new pills, prompting efforts to look for signs of such resistance and find combinations to…

The first Covid-19 antiviral pills that can be taken at home are a new treatment option for infected people, but they carry safety warnings and limitations that could complicate treatment…

U.S. regulators cleared use of a Covid-19 pill from Merck MRK -0.32% & Co. and partner Ridgeback Biotherapeutics LP, the latest…

U.S. health regulators cleared use of a Covid-19 pill from Pfizer Inc., the first drug that newly infected patients can now take at home to stay out of the…

The bright orange capsule that could transform Covid-19 treatment wasn’t on the radar in January 2020 when the pandemic was unfolding.The drug had never been tested in humans. Lab…

Merck & Co. and partner Ridgeback Biotherapeutics LP said Monday they have filed an application asking U.S. health regulators to authorize their Covid-19 pill, the next step toward…

Merck MRK 0.03% & Co. and its partner Ridgeback Biotherapeutics LP said their experimental Covid-19 pill helped prevent high-risk…

By Associated Press WASHINGTON: Merck & Co. said Friday that its experimental COVID-19 pill reduced hospitalizations and deaths by half in people recently…